FI104950B - Menetelmä glipitsidiä sisältävän annosmuodon valmistamiseksi - Google Patents

Menetelmä glipitsidiä sisältävän annosmuodon valmistamiseksi Download PDF

Info

Publication number
FI104950B
FI104950B FI920956A FI920956A FI104950B FI 104950 B FI104950 B FI 104950B FI 920956 A FI920956 A FI 920956A FI 920956 A FI920956 A FI 920956A FI 104950 B FI104950 B FI 104950B
Authority
FI
Finland
Prior art keywords
glipizide
dosage form
compound
wall
molecular weight
Prior art date
Application number
FI920956A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI920956A0 (fi
Inventor
Patrick S-L Wong
Atul Devdatt Ayer
Anthony L Kuczynski
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of FI920956A0 publication Critical patent/FI920956A0/fi
Application granted granted Critical
Publication of FI104950B publication Critical patent/FI104950B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Lubrication Of Internal Combustion Engines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI920956A 1989-09-05 1992-03-04 Menetelmä glipitsidiä sisältävän annosmuodon valmistamiseksi FI104950B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40231489 1989-09-05
US07/402,314 US5024843A (en) 1989-09-05 1989-09-05 Oral hypoglycemic glipizide granulation
PCT/US1990/004981 WO1991003247A1 (en) 1989-09-05 1990-08-31 Dosage form for administering oral hypoglycemic glipizide
US9004981 1990-08-31

Publications (2)

Publication Number Publication Date
FI920956A0 FI920956A0 (fi) 1992-03-04
FI104950B true FI104950B (fi) 2000-05-15

Family

ID=23591411

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920956A FI104950B (fi) 1989-09-05 1992-03-04 Menetelmä glipitsidiä sisältävän annosmuodon valmistamiseksi

Country Status (20)

Country Link
US (2) US5024843A (ko)
EP (1) EP0490991B1 (ko)
JP (1) JP2919964B2 (ko)
KR (1) KR0157640B1 (ko)
AT (1) ATE94393T1 (ko)
AU (1) AU632859B2 (ko)
CA (1) CA2024502C (ko)
DE (1) DE69003392T2 (ko)
DK (1) DK0490991T3 (ko)
ES (1) ES2060199T3 (ko)
FI (1) FI104950B (ko)
GR (1) GR1000932B (ko)
HK (1) HK116897A (ko)
IE (1) IE62594B1 (ko)
MX (1) MX171191B (ko)
NO (1) NO303963B1 (ko)
NZ (1) NZ235127A (ko)
PT (1) PT95169B (ko)
WO (1) WO1991003247A1 (ko)
ZA (1) ZA906972B (ko)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361795B1 (en) * 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
WO1998001117A1 (en) 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
WO1998018452A1 (en) * 1996-10-25 1998-05-07 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ZA979605B (en) * 1996-11-25 1998-05-21 Alza Corp Ascending-dose dosage form.
EP1782798A3 (en) * 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
CA2265668C (en) * 1996-11-25 2005-08-23 Alza Corporation Methylphenidate tablet
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
JP3893058B2 (ja) * 1999-09-30 2007-03-14 ペンウェスト ファーマシューティカルズ カンパニー 高度に可溶性の薬物のための徐放性マトリックス系
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
AU5459201A (en) * 2000-05-30 2001-12-11 Add Advanced Drug Delivery Technologies Ag Peroral therapeutic system comprising glipizide
WO2001091717A1 (en) * 2000-05-30 2001-12-06 Add Advanced Drug Delivery Technologies Ag Oral delivery form comprising glipizide
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US7130822B1 (en) * 2000-07-31 2006-10-31 Cognos Incorporated Budget planning
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
CA2441064A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0213079A (pt) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
EP1471887B1 (en) * 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US20040052848A1 (en) * 2002-05-23 2004-03-18 Xiu-Xiu Cheng Biguanide formulations
EP1551457A1 (en) * 2002-07-16 2005-07-13 Elan Pharma International Limited Liquid dosage compositions of stable nanoparticulate active agents
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20060002998A1 (en) * 2002-11-15 2006-01-05 Anupam Trehan Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
AU2004285532A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Administration of levodopa and carbidopa
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
CN101448498B (zh) 2006-05-16 2011-04-27 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
CN100571783C (zh) * 2006-10-30 2009-12-23 北京红林制药有限公司 格列吡嗪控释片及其制备方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) * 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
WO2010022140A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
WO2010148409A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
CN101940578B (zh) * 2010-08-25 2012-07-25 山东新华制药股份有限公司 一种用于治疗2型糖尿病的药物组合物及其制备方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
LT3019167T (lt) 2013-07-12 2021-03-25 Knopp Biosciences Llc Eozinofilų ir (arba) bazofilų padidintų kiekių gydymas
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
MY102980A (en) * 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation

Also Published As

Publication number Publication date
EP0490991A1 (en) 1992-06-24
NO303963B1 (no) 1998-10-05
MX171191B (es) 1993-10-06
AU6417590A (en) 1991-04-08
EP0490991B1 (en) 1993-09-15
CA2024502C (en) 1991-03-06
NO920740D0 (no) 1992-02-25
ZA906972B (en) 1991-06-26
NZ235127A (en) 1993-02-25
DE69003392D1 (de) 1993-10-21
KR920703066A (ko) 1992-12-17
JPH05500222A (ja) 1993-01-21
AU632859B2 (en) 1993-01-14
KR0157640B1 (ko) 1998-11-16
DE69003392T2 (de) 1994-01-13
JP2919964B2 (ja) 1999-07-19
GR900100659A (en) 1992-01-20
HK116897A (en) 1997-09-05
IE62594B1 (en) 1995-02-08
NO920740L (no) 1992-02-25
IE903166A1 (en) 1991-03-13
PT95169A (pt) 1991-05-22
ATE94393T1 (de) 1993-10-15
DK0490991T3 (da) 1993-11-29
CA2024502A1 (en) 1991-03-06
PT95169B (pt) 1998-06-30
US5545413A (en) 1996-08-13
FI920956A0 (fi) 1992-03-04
GR1000932B (el) 1993-03-16
WO1991003247A1 (en) 1991-03-21
US5024843A (en) 1991-06-18
ES2060199T3 (es) 1994-11-16

Similar Documents

Publication Publication Date Title
FI104950B (fi) Menetelmä glipitsidiä sisältävän annosmuodon valmistamiseksi
US5091190A (en) Delivery system for administration blood-glucose lowering drug
AU685297B2 (en) Tacrine pharmaceutical compositions
KR0137731B1 (ko) 방출 지연성 투여형 약물
CA2265668C (en) Methylphenidate tablet
KR100387344B1 (ko) 항간질약물에효과적인제형
JP4393587B2 (ja) 医薬の上昇性投与量を提供するための薬剤投与型
US5591454A (en) Method for lowering blood glucose
MXPA05001184A (es) Formulaciones y formas de dosificacion para administracion controlada de topiramato.
JPH0798748B2 (ja) ベラパミルの投与用製剤
USRE44459E1 (en) Method for lowering blood glucose
EP1782798A2 (en) Ascending-dose dosage form
JPH0784385B2 (ja) 有用な薬剤クロルフエニラミン供給用剤形
CN112741806A (zh) 一种用于老年痴呆症的缓控释给药***
US20020197309A1 (en) Method for lowering blood glucose